By Barbara Obstoj-Cardwell. Editor
Two of the world’s largest pharmaceutical companies - Merck & Co and Pfizer - last week reported second-quarter financial results that were seriously impacted by the decline in the need for COVID-19 vaccines and treatments, but still came out with impressive figures. Troubled US biotech EQRx, which launched with the promise of reforming drug pricing, has given up its dream and accepted an all-stock merger proposal from Revolution Medicines. Japanese drugmakers Sumitomo Pharma and Otsuka suffered a setback in their two clinical trials of the schizophrenia candidate ulotaront.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze